Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia
David G. Cotter, … , Gary J. Patti, Peter A. Crawford
David G. Cotter, … , Gary J. Patti, Peter A. Crawford
Published December 1, 2014; First published October 27, 2014
Citation Information: J Clin Invest. 2014;124(12):5175-5190. https://doi.org/10.1172/JCI76388.
View: Text | PDF
Categories: Research Article Hepatology

Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia

  • Text
  • PDF
Abstract

Nonalcoholic fatty liver disease (NAFLD) spectrum disorders affect approximately 1 billion individuals worldwide. However, the drivers of progressive steatohepatitis remain incompletely defined. Ketogenesis can dispose of much of the fat that enters the liver, and dysfunction in this pathway could promote the development of NAFLD. Here, we evaluated mice lacking mitochondrial 3-hydroxymethylglutaryl CoA synthase (HMGCS2) to determine the role of ketogenesis in preventing diet-induced steatohepatitis. Antisense oligonucleotide–induced loss of HMGCS2 in chow-fed adult mice caused mild hyperglycemia, increased hepatic gluconeogenesis from pyruvate, and augmented production of hundreds of hepatic metabolites, a suite of which indicated activation of the de novo lipogenesis pathway. High-fat diet feeding of mice with insufficient ketogenesis resulted in extensive hepatocyte injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concentrations, and impaired hepatic gluconeogenesis due to sequestration of free coenzyme A (CoASH). Supplementation of the CoASH precursors pantothenic acid and cysteine normalized TCA intermediates and gluconeogenesis in the livers of ketogenesis-insufficient animals. Together, these findings indicate that ketogenesis is a critical regulator of hepatic acyl-CoA metabolism, glucose metabolism, and TCA cycle function in the absorptive state and suggest that ketogenesis may modulate fatty liver disease.

Authors

David G. Cotter, Baris Ercal, Xiaojing Huang, Jamison M. Leid, D. André d’Avignon, Mark J. Graham, Dennis J. Dietzen, Elizabeth M. Brunt, Gary J. Patti, Peter A. Crawford

×

Figure 1

Ketogenic insufficiency in mice treated with HMGCS2 ASO.

Options: View larger image (or click on image) Download as PowerPoint
Ketogenic insufficiency in mice treated with HMGCS2 ASO.
(A) Immunoblot ...
(A) Immunoblot for HMGCS2 and actin using protein lysates derived from livers of neonatal mice treated with either a scrambled sequence control ASO or HMGCS2 ASO. Mice were treated with ASO daily for 11 days, beginning on the second day of life, and tissues and serum were collected on P12. Normalized protein abundance is quantified below. (B) Serum total ketone body (TKB) concentrations (mM) and (C) hepatic TAG concentrations (mg/g tissue) on P12 in ASO-treated mice n = 4–6/group. (D) Immunoblot for HMGCS2 and actin using protein lysates derived from the livers of adult mice treated with control or HMGCS2 ASO biweekly for 4 weeks beginning at 6 weeks of age. (E) Serum TKB concentrations (mM) during fasting in adult mice treated with ASOs for 4 weeks. n = 3–5/group. *P < 0.05, ***P < 0.001 by Student’s t test versus HMGCS2 ASO–treated mice, or as indicated.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts